HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination ...

Cutting-edge clinical research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is being shared this ...

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

There is a wide selection of therapies available for advanced prostate cancer treatment, but the optimal strategy for them is ...